GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Geovax Labs Inc (NAS:GOVX) » Definitions » 5-Year RORE %

Geovax Labs (Geovax Labs) 5-Year RORE % : -99.99% (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Geovax Labs 5-Year RORE %?

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. Geovax Labs's 5-Year RORE % for the quarter that ended in Dec. 2023 was -99.99%.

The industry rank for Geovax Labs's 5-Year RORE % or its related term are showing as below:

GOVX's 5-Year RORE % is ranked worse than
97.19% of 1067 companies
in the Biotechnology industry
Industry Median: -7.34 vs GOVX: -99.99

Geovax Labs 5-Year RORE % Historical Data

The historical data trend for Geovax Labs's 5-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Geovax Labs 5-Year RORE % Chart

Geovax Labs Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
5-Year RORE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 31.17 - -68.82 - -99.99

Geovax Labs Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
5-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -51.62 -99.75 -99.95 -99.99

Competitive Comparison of Geovax Labs's 5-Year RORE %

For the Biotechnology subindustry, Geovax Labs's 5-Year RORE %, along with its competitors' market caps and 5-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Geovax Labs's 5-Year RORE % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Geovax Labs's 5-Year RORE % distribution charts can be found below:

* The bar in red indicates where Geovax Labs's 5-Year RORE % falls into.



Geovax Labs 5-Year RORE % Calculation

Geovax Labs's 5-Year RORE % for the quarter that ended in Dec. 2023 is calculated as:

5-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 5-year -Cumulative Dividends per Share for 5-year )
=( -14.29--1358862.584 )/( -1359000.221-0 )
=1358848.294/-1359000.221
=-99.99 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 5-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Dec. 2023 and 5-year before.


Geovax Labs  (NAS:GOVX) 5-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 5-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


Geovax Labs 5-Year RORE % Related Terms

Thank you for viewing the detailed overview of Geovax Labs's 5-Year RORE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Geovax Labs (Geovax Labs) Business Description

Traded in Other Exchanges
Address
1900 Lake Park Drive, Suite 380, Smyrna, GA, USA, 30080
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors.
Executives
Mckee Kelly T. Jr. officer: Chief Medical Officer 233 VALLEY MEADOW DRIVE, CHAPEL HILL NC 27516
David A Dodd director C/O SEROLOGICALS CORP, 5565 SPALDING DR, NORCROSS GA 30092
Mark Reynolds officer: Chief Financial Officer TWO BALA PLAZA, SUITE 300, PHILADELPHIA PA 19004
Jayne Morgan director 1900 LAKE PARK DRIVE, SUITE 380, SMYRNA GA 30080
Randal D Chase director 28 GEORGIA COURT, RICHMOND HILL A6 L4E ON7
Nicole Lemerond director 3 MURRAY HILL ROAD, SCARSDALE NY 10583
John W. Sharkey officer: VP, Business Development 16857 E. SAGUARO BLVD., FOUNTAIN HILLS AZ 85268
Dean G Kollintzas director 1256 BRIARCLIFF ROAD N.E., EMTECH BIO SUITE 500, ATLANTA GA 30306
Spencer John N Jr director 2859 PACES FERRY RD, STE 1000, ATLANTA GA 30339
Robert T Mcnally director
Farshad Guirakhoo officer: Sr VP, Research & Development 39 CHESTNUT STREET, MELROSE MA 02176
Steven S. Antebi director 10550 FONTENELLE WAY, LOS ANGELES CA 90077
Harriet L Robinson other: Chair, Scientific Adv Brd 1256 BRIARCLIFF ROAD N.E., EMTECH BIO SUITE 500, ATLANTA GA 30306
Mark J Newman officer: VP, Research & Development 1900 LAKE PARK DR, SUITE 380, SMYRNA GA 30080
Peter M Tsolinas director 123 JOAN DRIVE, BARRINGTON IL 60010